Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jul 6, 2023

David Dodd is Chairman, President, and CEO of GeoVax, which is working on vaccines that overcome restrictions of mRNA vaccines to provide longer-term, more robust protection, particularly for people who do not respond well to primary antibody stimulation. There is a strong response from T cells from this vaccine which can be stored in a non-refrigerated freeze-dried form allowing for greater access in more regions of the world.

David explains, "We are targeting those individuals who have compromised immune systems. This is a category of approximately 15 million individuals in the United States and almost 250 million worldwide, who, as a result of the conditions of their body or maybe even the therapies they may be on, or other conditions. Their body does not respond appropriately or well to the existing approved vaccines for COVID-19 or to the monoclonal antibodies. It's not that the other products have no value - it's that the individuals' bodies have been depleted of the ability to mount the proper response."

"We also include what is known as the nucleocapsid protein, which is highly conserved across viruses. It's always there, and it induces a very strong T cell response which drives memory in vaccines or in the human body from an immune standpoint. So, it is memory durability and also that it enables people whose bodies may have been depleted in order to mount an antibody response. They now can rely upon their T cells system or their cellular immune system to give them a protective element to reduce the severity, hospitalization, and risk of death."

#GeoVax #Vaccines #VaccineFatigue #Biodefense #COVID #VaccineAccess #VaccinePreparedness #TCells

Listen to the podcast here